Dr. Harvey Fineberg, president of the Gordon and Betty Moore Foundation, joins Dana Goldman in a wide ranging conversation about the future of American healthcare. Dr. Fineberg’s expertise spans a range of topics from immunization programs to AIDS prevention to 21st century health threats and emerging diseases.
- Event Date
- Tuesday, July 28, 2020
1:00 PM - 1:45 PM Pacific
Harvey V. Fineberg, MD, PhD
President, Gordon and Betty Moore Foundation
Harvey V. Fineberg, MD, PhD, is co-author of The Epidemic That Never Was, an analysis of the controversial U.S. immunization program against swine flu in 1976. He has co-edited books on such diverse topics as AIDS prevention, vaccine safety, understanding risk in society, and global health and has authored numerous articles published in professional journals. Dr. Fineberg chairs the standing committee on emerging disease threats and 21st century health threats of the National Academies of Sciences, Engineering and Medicine.
Dr. Fineberg is president of the Gordon and Betty Moore Foundation and board chair of the Science Philanthropy Alliance. He previously served as president of the U.S. Institute of Medicine (now National Academy of Medicine), as provost of Harvard University, and as dean of the Harvard Chan School of Public Health. Dr. Fineberg is a trustee and former board chair of the Carnegie Endowment for International Peace.
Dana Goldman, PhD
Leonard D. Schaeffer Director's Chair, USC Schaeffer Center
Interim Dean, USC Price School of Public Policy
Distinguished Professor of Public Policy, Pharmacy & Economics, USC School of Pharmacy and the USC Price School of Public Policy
Dana Goldman, PhD, is the Leonard D. Schaeffer Chair and a Distinguished Professor of Pharmacy, Public Policy, and Economics at the University of Southern California. He also directs the USC Schaeffer Center for Health Policy and Economics, a research hub for one of the nation’s premier health policy and management programs in the Sol Price School of Public Policy and School of Pharmacy.
Goldman is the author of approximately 250 articles and book chapters in medicine, health policy, economics, and statistics. He has served—or is serving—as a health policy advisor to the Congressional Budget Office, Covered California (the California insurance exchange), and the Fred Hutchinson Cancer Institute’s Outcomes Research External Advisory Board. He is a founding editor of the Forum for Health Economics and Policy, and serves on several editorial boards including Health Affairs and the American Journal of Managed Care. He is a former director of the International Society for Pharmacoeconomics and Outcomes Research and the American Society of Health Economists. Goldman's work has been featured in The New York Times, The Wall Street Journal, Forbes, The Washington Post, Business Week, U.S. News and World Report, The Economist, NBC Nightly News, CNN, National Public Radio, and other media.
Goldman is an elected member of the National Academy of Medicine and the National Academy of Social Insurance. In 2016, he was appointed a Distinguished Professor at the University of Southern California in honor of accomplishments that have brought the University special renown. He is a past recipient of the MetLife Foundation Silver Scholar Award, honoring his research to define the value of healthy aging and medical innovations to help individuals live healthier and longer lives; the Eugene Garfield Economic Impact Prize, recognizing outstanding research demonstrating how medical research impacts the economy; the National Institute for Health Care Management Research Foundation award for excellence in health policy; and the Alice S. Hersh New Investigator Award recognizing contributions of a young scholar to health services research.
Goldman is also an Adjunct Professor of Health Services at UCLA and a research associate with the National Bureau of Economic Research. He was a co-founder of Precision Health Economics, a consultancy that provides services to health insurance, pharmaceutical, biological and health care technology companies, and he currently serves as a consultant to the firm. He serves on a scientific advisory board to ACADIA Pharmaceuticals. Prior to arriving at USC, he spent 15 years at the RAND Corporation, where he held the Distinguished Chair in Health Economics and served as director of RAND's program in Health Economics, Finance, and Organization and the Bing Center for Health Economics.
Goldman received his BA summa cum laude from Cornell University and a PhD in Economics from Stanford University.